Geron Corp
Veridion Score
Composite trend over time
Why is GERN moving today?
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for GERN.
GERN insider activity
Geron Corp
No multi-insider buying cluster in the last 90 days
Net buying: $12K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 2026-06-30 | Spiegel Robert J. | Insider | buy | $1.28 | 6,103 | 205,810 | $8K | SEC Form 4 |
| 2026-04-01 | 2026-03-31 | Spiegel Robert J. | Insider | buy | $1.49 | 5,243 | 199,707 | $8K | SEC Form 4 |
| 2026-02-19 | 2026-02-18 | ROBERTSON MICHELLE | Insider | sell | $1.94 | 9,855 | 17,645 | $19K | SEC Form 4 |
| 2026-01-05 | 2025-12-31 | Spiegel Robert J. | Insider | buy | $1.32 | 5,918 | 194,464 | $8K | SEC Form 4 |
| 2025-10-01 | 2025-09-30 | Spiegel Robert J. | Insider | buy | $1.37 | 5,702 | 188,546 | $8K | SEC Form 4 |
GERN contract awards, year to date.
Public federal awards linked to this ticker.
GERN lobbying filings, year to date.
Registered lobbying filings matched to Geron Corp.